Epstein‐Barr virus seroreactivity among unaffected individuals within high‐risk nasopharyngeal carcinoma families in Taiwan
Open Access
- 2 June 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 111 (1), 117-123
- https://doi.org/10.1002/ijc.20222
Abstract
Most adults have been infected with EBV. Many studies have indicated that antibodies against specific EBV antigens, particularly IgA antibodies, can be predictive or prognostic of EBV-associated malignancies, such as NPC. We hypothesized that healthy individuals from families with a history of multiple members affected with NPC (who therefore might be genetically susceptible to NPC themselves) might have an EBV antibody profile that is distinct from that seen in healthy individuals from the community at large. To explore this possibility and examine determinants of anti-EBV antibody levels in healthy, high-risk individuals, we evaluated data from 2 parallel studies of NPC in Taiwan, which included 1,229 healthy members of families in which 2 or more individuals were affected with NPC and 320 controls from the community at large. Blood collected from participants was tested for IgA antibodies against EBV VCA and EBNA-1 and for neutralizing antibodies against EBV DNase using standard assays. We observed evidence of familial aggregation of EBV seroreactivity among individuals from high-risk, multiplex NPC families. Anti-VCA IgA and anti-EBNA-1 IgA antibody seroprevalence in unaffected family members of NPC cases was 5–6 times higher than in members of the community (p < 0.01). This elevated seroprevalence among unaffected individuals from high-risk families was observed regardless of the relationship of the unaffected individual to the closest affected relative (siblings, parents, children or spouses). No sociodemographic or environmental factors examined were found to strongly and consistently correlate with elevated seroprevalence, but patterns emerged of increasing seroprevalence among older individuals and among females. Unaffected individuals from high-risk NPC families have elevated anti-EBV IgA antibody titers. The etiologic and clinical implications of this finding remain to be established.Keywords
This publication has 35 references indexed in Scilit:
- Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000
- Epstein–Barr virus-associated malignancies: epidemiologic patterns and etiologic implicationsCritical Reviews in Oncology/Hematology, 2000
- Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated DiseasesThe Journal of Immunology, 2000
- Nasopharyngeal CarcinomaPublished by Springer Nature ,1997
- Antibodies to LMP2A/2B in EBV-carrying malignanciesEuropean Journal Of Cancer, 1995
- Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6European Journal Of Cancer, 1993
- Hodgkin's Disease and Epstein-Barr VirusNew England Journal of Medicine, 1989
- Prospective studies on nasopharyngeal carcinoma in epstein‐barr virus IgA/VCA antibody‐positne persons in Wuzhou city, chinaInternational Journal of Cancer, 1985
- Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinomaInternational Journal of Cancer, 1976